{
  "docId": "019de071-753f-7227-aa1d-36a319c59353",
  "docSlug": "7013d0966bfedd0d757b9fa24a480455",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 34,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-like arrow structure to represent lines of therapy (1L, 2L, 3L+).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/18",
  "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
  "deckJsonHref": "/decks/019de071-753f-7227-aa1d-36a319c59353.json",
  "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.4,
        "y": 0.24
      },
      "kind": "list",
      "text": "1L: Trastuzumab + pertuzumab + taxane, CLEOPATRA: mPFS = 18.7 months",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07cdb73e-d7d3-4856-b269-7236bd6e0761",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.28,
        "x": 0.4,
        "y": 0.63
      },
      "kind": "list",
      "text": "2L+: T-DM1, EMILIA: mPFS = 9.6 months",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "668e1d52-3389-4d53-8e5d-9a9dc393065e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.52,
        "x": 0.4,
        "y": 0.48
      },
      "kind": "list",
      "text": "2L: T-DXd, DESTINY-Breast03: mPFS = not yet reached, Investigator-assessed PFS: 25.1 months",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87dc4edf-e2dc-4b90-950e-86f3094b8869",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.4,
        "y": 0.36
      },
      "kind": "list",
      "text": "1L: T-DM1 + pertuzumab, MARIANNE: mPFS = 15.2 months",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed183ca-854f-42e6-87aa-1f77efc0d6ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.41,
        "x": 0.4,
        "y": 0.75
      },
      "kind": "list",
      "text": "3L+: T-DXd, DESTINY-Breast01: mPFS = 19.4 months",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1b62216-72db-4b7d-bf8c-b6bf7a311559",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.07,
        "y": 0.358
      },
      "kind": "paragraph",
      "text": "Second-line monotherapy data that rivals first-line current standard triplet therapy. Consistency across all sub-groups. Improved safety profile.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2a0da38-19d5-4768-806d-d4044c374ffc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Swain SM, Baselga J et al. N Engl J Med. 2015;372:724-34. 2. Perez J et al. Expert Opin Biol Ther. 2021;21:811-24 3. Cortés, J, Presented at ESMO 2021, Abstract LBA1 on 18 September 2021. 4. Verma S et al. N Engl J Med. 2012;367:1783-91 5. DB01: Modi S et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c29cbfb9-ff02-4b40-9b54-e2bf34bff42d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "T-DXd transforms the treatment paradigm for patients with metastatic HER2+ breast cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4189844-b18f-4fc5-adcd-222ddcd8d767",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 17,
      "beatId": "b84365e9-a163-4557-b2fe-beb8ac4c4175",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Key takeaways and future prospects for Enhertu",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}